The estimated Net Worth of Rick E Winningham is at least $15.5 Million dollars as of 11 August 2023. Mr. Winningham owns over 1,241 units of Theravance Biopharma Inc stock worth over $84,596 and over the last 15 years he sold TBPH stock worth over $9,480,694. In addition, he makes $5,932,410 as Chairman of the Board und Chief Executive Officer at Theravance Biopharma Inc.
Rick has made over 18 trades of the Theravance Biopharma Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 1,241 units of TBPH stock worth $171,457 on 11 August 2023.
The largest trade he's ever made was buying 80,000 units of Theravance Biopharma Inc stock on 14 August 2015 worth over $948,800. On average, Rick trades about 3,179 units every 53 days since 2010. As of 11 August 2023 he still owns at least 10,444 units of Theravance Biopharma Inc stock.
You can see the complete history of Mr. Winningham stock trades at the bottom of the page.
Rick E. Winningham serves as Chairman of the Board, Chief Executive Officer of the Company. He has served as our Chief Executive Officer since our spin-off from Innoviva in June 2014. From October 2001 to August 2014, Mr. Winningham served as Chief Executive Officer of Innoviva, where he also served as Chairman of the board of directors from April 2010 to October 2014. From 1997 to 2001 he served as President, Bristol Myers Squibb Oncology/Immunology/Oncology Therapeutics Network (OTN) and also as President of Global Marketing from 2000 to 2001. In addition to operating responsibility for U.S. Oncology/Immunology/OTN at Bristol Myers Squibb (BMS), Mr. Winningham also had full responsibility for Global Marketing in the Cardiovascular, Infectious Disease, Immunology, Oncology/Metabolics and GU/GI/Neuroscience therapeutic areas. Over a fifteen year period beginning in 1986 with BMS and its predecessor, Bristol Myers, Mr. Winningham held various U.S. and global management positions. Mr. Winningham is a member of Biotechnology Industry Organization's board of directors and serves on the Health Section Governing Board Standing Committee on Reimbursement. Mr. Winningham served as a Director on the board of directors of the California Healthcare Institute ("CHI") from November 2011 to March 2015. He was elected Chairman of CHI in January 2014, a position he held until CHI merged with Baybio to become the California Life Sciences Association ("CLSA") in March 2015. Mr. Winningham is on the board of CLSA, and served as its chairman from March 2015 to November 2015. He is a member of the board of directors of Jazz Pharmaceuticals plc and of OncoMed Pharmaceuticals, Inc. Mr. Winningham holds an M.B.A. from Texas Christian University and a B.S. degree from Southern Illinois University.
As the Chairman of the Board und Chief Executive Officer of Theravance Biopharma Inc, the total compensation of Rick Winningham at Theravance Biopharma Inc is $5,932,410. There are no executives at Theravance Biopharma Inc getting paid more.
Rick Winningham is 60, he's been the Chairman of the Board und Chief Executive Officer of Theravance Biopharma Inc since . There are 11 older and 15 younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.
Rick's mailing address filed with the SEC is C/O THERAVANCE BIOPHARMA US, INC., 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 11 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva, und Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Theravance Biopharma Inc executives and other stock owners filed with the SEC include: